A 3-year analysis of a phase IIIb trial found that bimekizumab, a dual interleukin-17A and interleukin-17F inhibitor, maintained high rates of skin clearance and demonstrated a consistent safety profile in patients with moderate-to-severe plaque psoriasis, including those who switched from secukinumab, an interleukin-17A inhibitor.
Neuroimaging detects reduced grey matter in multiple brain regions among breast cancer patients after chemotherapy, raising concern for long-term cognitive risks.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
The Colorectal Cancer Alliance and partners are urging the Department of Health and Human Services to preserve U.S. Preventive Services Task Force’s evidence-based role in safeguarding access to no-cost colorectal cancer screening.